RNS Number : 6711U
30 March 2023
30 March 2023 07:00 BST
License agreement with KYM Biosciences for CMG901, a
Claudin-18.2 antibody drug conjugate, completed
AstraZeneca has completed an exclusive global license agreement
with KYM Biosciences Inc.(i) for CMG901, a potential first-in-class
antibody drug conjugate (ADC) targeting Claudin 18.2, a promising
therapeutic target in gastric cancers.
CMG901 is currently being evaluated in a Phase I trial for the
treatment of Claudin 18.2-positive solid tumours, including gastric
cancer. Preliminary results from the trial have shown an
encouraging profile for CMG901, with early signs of anti-tumour
activity across the dose levels tested.
AstraZeneca has entered into an exclusive global license for the
research, development, manufacture and commercialisation of CMG901
for an upfront payment of $63m, with potential development and
sales-related milestone payments of up to $1.1bn and tiered
royalties up to low double digits.
The transaction does not impact AstraZeneca's financial guidance
i. KYM Biosciences is a joint venture established by affiliates
of Keymed Biosciences and Lepu Biopharma.
CMG901 is a novel antibody drug conjugate targeting Claudin
18.2, and consists of an anti-Claudin 18.2 monoclonal antibody, a
protease-degradable linker, and a cytotoxic small molecule
monomethyl auristatin E (MMAE). CMG901 is being developed for the
treatment of solid tumours that express the cell surface protein
Claudin 18.2, including gastric cancers. CMG901 is owned by KYM
Biosciences Inc. (KYM), a joint venture established by affiliates
of Keymed Biosciences (70% of KYM ownership) and Lepu Biopharma
(30% of KYM ownership).
AstraZeneca in gastrointestinal cancers
AstraZeneca has a broad development programme for the treatment
of gastrointestinal (GI) cancers across several medicines and a
variety of tumour types and stages of disease. In 2020, GI cancers
collectively represented approximately 5.1 million new cancer cases
leading to approximately 3.6 million deaths.(1)
Within this programme, the Company is committed to improving
outcomes in gastric, liver, biliary tract, oesophageal, pancreatic
and colorectal cancers.
Imfinzi (durvalumab) is approved in the US in combination with
chemotherapy (gemcitabine plus cisplatin) for advanced biliary
tract cancer and in combination with Imjudo in unresectable
hepatocellular carcinoma. Imfinzi is being assessed in
combinations, including with Imjudo in liver, oesophageal and
gastric cancers in an extensive development programme spanning
early to late-stage disease across settings.
Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug
conjugate, is approved in HER2-positive advanced gastric cancer and
is being assessed in colorectal cancer. Enhertu is jointly
developed and commercialised by AstraZeneca and Daiichi Sankyo.
Lynparza (olaparib), a first-in-class PARP inhibitor, is
approved in BRCA-mutated metastatic pancreatic cancer. Lynparza is
developed and commercialised in collaboration with MSD (Merck &
Co., Inc. inside the US and Canada).
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the
ambition to provide cures for cancer in every form, following the
science to understand cancer and all its complexities to discover,
develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers.
It is through persistent innovation that AstraZeneca has built one
of the most diverse portfolios and pipelines in the industry, with
the potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @ AstraZeneca .
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
1. World Health Organization. World Cancer Fact Sheet. Available
. Accessed March 2023.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
March 30, 2023 02:00 ET (06:00 GMT)
Gráfico Histórico do Ativo
De Abr 2023 até Mai 2023
Gráfico Histórico do Ativo
De Mai 2022 até Mai 2023